Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $12.55 and traded as high as $13.47. Merrimack Pharmaceuticals shares last traded at $13.44, with a volume of 29,917 shares traded. Analysts Set New Price Targets Separately, StockNews.com […]
Merrimack Pharmaceuticals (NASDAQ:MACK – Get Free Report) and Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership. Earnings & Valuation This table compares Merrimack […]
StockNews.com lowered shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) from a hold rating to a sell rating in a report issued on Tuesday. Merrimack Pharmaceuticals Stock Down 0.4 % MACK stock opened at $13.25 on Tuesday. The business has a fifty day moving average of $13.10 and a two-hundred day moving average of $12.52. […]
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $12.40 and traded as high as $13.39. Merrimack Pharmaceuticals shares last traded at $13.32, with a volume of 36,749 shares. Analyst Ratings Changes Separately, StockNews.com upgraded shares […]
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) Director Eric Andersen bought 101,050 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was bought at an average cost of $12.85 per share, for a total transaction of $1,298,492.50. Following the completion of the transaction, the director now directly […]